Biography for Eric Palmer
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family.
Articles by Eric Palmer
Biogen Idec has encountered its share of manufacturing headaches because of the multiple sclerosis drug Tysabri that it acquired from Elan. It will now have to add to that list some limited FDA concerns over its API manufacturing.
Biosimilars are expected to become a significant piece of the generics business worldwide, and Alvogen is spending $250 million to build a facility in Iceland to develop and manufacture biosimilars.
India's Jubilant Life Sciences has received a second warning letter this year for its operations in North America. This time, the company landed in hot water for problems at its Jubilant HollisterStier sterile manufacturing plant in Spokane, WA.
Ranbaxy Laboratories got into the vaccine manufacturing business a few years ago, but now it may be looking to get out as its regulatory problems pile up. According reports, Ranbaxy is likely to sell Biovel, the vaccine company it bought in 2010.
Manufacturing facilities in India that are approved by Western regulators are a hot commodity, and that is what Bafna Pharmaceuticals has. The Indian drugmaker is for sale and is reportedly drawing interest from potential buyers, including Mylan as well as some Indian drugmakers.
LTS Lohmann, which Novartis owns a big piece of, is reportedly attracting bids of about $1.6 billion from private equity investors who want its expertise in the growing niche of manufacturing transdermal patches.
Two smaller players in the OTC drug industry have decided to join their manufacturing and distribution forces to cash in on retailers' hunger for private-label products and position the expanded company as an alternative to OTC colossus Perrigo.
GlaxoSmithKline, already in the midst of an expansion at an active pharmaceutical ingredient plant in Scotland, has decided to add even more capacity with a little financial help from the government.
Paul S. Levy, co-founder of the investment group that just announced a $2.6 billion deal to buy DSM Pharmaceutical Products and merge it with Patheon, sees opportunity in rolling up more players into a larger company. But with other private investors in the market, he may find competition looking over the same targets.
Pharma likes India for manufacturing because of its low costs. But costs are relative, and domestic contract manufacturers there are having a hard go of late as the country's currency has fallen in the face of economic issues there and government incentives have begun to fall away.